ANI Pharmaceuticals (ANIP) Stock Statistics & Valuation Metrics

ANI Pharmaceuticals has a market cap or net worth of $2.03B. The enterprise value is $1.75B.

ANI Pharmaceuticals has 21,688,772 shares outstanding. The number of shares has decreased by -2.65% in one year.

ANI Pharmaceuticals’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is 0.04%.

The current PE Ratio of ANI Pharmaceuticals is ―. ANI Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, ANI Pharmaceuticals had revenue of 614.38M and earned -18.52M in profits. Earnings per share was -1.04.

In the last 12 months, operating cash flow was 139.14M and capital expenditures -31.78M, giving a free cash flow of 111.37M billion.

ANI Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

ANI Pharmaceuticals upcoming earnings date is Nov 5, 2025, Before Open (Confirmed).

ANI Pharmaceuticals as a current ratio of 2.72, with Debt / Equity ratio of 73.29%

In the past 12 months, ANI Pharmaceuticals has paid -3.69M in taxes.

ANI Pharmaceuticals EV to EBITDA ratio is 19.55, with an EV/FCF ratio of 32.87.

ANI Pharmaceuticals has $217.80M in cash and marketable securities with $320.08M in debt, giving a net cash position of $102.28M billion.

Gross margin is 57.95%, with operating margin of 0.10%, and net profit margin of -3.01%.

The average price target for ANI Pharmaceuticals is $91.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy